Research graph
References from Case Report: Faricimab in the treatment of subretinal fluid secondary to choroidal osteoma without definite evidence of CNV. Local targets link to admitted publications; unresolved targets remain external evidence.
Bilaterale chorioidale osteome
10.1055/s-2008-1045680 · 1993 · External reference
Choroidal osteoma
10.1001/archopht.1978.03910050204002 · 1978 · External reference
Outcomes of anti–vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma
10.1097/iae.0000000000000187 · 2014 · External reference
Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma
10.1038/eye.2016.50 · 2016 · External reference
Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: long-term results
10.4103/0974-620x.169908 · 2015 · External reference
Complications, treatments, and visual prognosis of choroidal osteomas
10.1007/s00417-021-05487-4 · 2022 · External reference
Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma
10.1097/iae.0b013e3181c720ca · 2010 · External reference
Choroidal neovascular membranes in retinal and choroidal tumors: origins, mechanisms, and effects
10.3390/ijms24021064 · 2023 · External reference
Choroidal osteoma: the varied response of subretinal fluid to anti-VEGF agents
10.1136/bcr-2020-234357 · 2020 · External reference
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials
10.1016/s0140-6736(22)00010-1 · 2022 · External reference
TENAYA And LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2
10.1016/j.ophtha.2024.02.014 · 2024 · External reference
Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials
10.1016/j.ophtha.2023.12.026 · 2024 · External reference
Clinical features and therapeutic management of choroidal osteoma: a systematic review
10.1016/j.survophthal.2023.06.002 · 2023 · External reference
Predicting visual outcomes in choroidal osteoma treated with anti-vascular endothelial growth factor
10.1016/j.ajo.2022.08.007 · 2022 · External reference
[Long-term outcome of macular neovascularization secondary to choroidal osteoma with and without intravitreal anti-VEGF(vascular endothelial growth factor)- treatment]
10.1007/s00347-023-01912-7 · 2023 · External reference
Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: long-term results
10.4103/0974-620x.169908 · 2015 · External reference
Antivascular endothelial growth factorsfor the management of choroidal neovascularization associated with choroidal osteoma: a case study-based review
10.4103/joco.joco_74_24 · 2024 · External reference
Anatomic outcomes with faricimab vs aflibercept in the head-to-head dosing phase of the TENAYA/LUCERNE trials in neovascular age-related macular degeneration
10.1016/j.ophtha.2024.11.023 · 2025 · External reference
Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis
10.1007/s40123-025-01181-4 · 2025 · External reference
Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: a case report
10.1177/03000605261445216 · 2026 · External reference
Choroidal osteoma
10.1001/archopht.1978.03910050204002 · ExternalCitation · doi-reference
[Long-term outcome of macular neovascularization secondary to choroidal osteoma with and without intravitreal anti-VEGF(vascular endothelial growth factor)- treatment]
10.1007/s00347-023-01912-7 · ExternalCitation · doi-reference
Complications, treatments, and visual prognosis of choroidal osteomas
10.1007/s00417-021-05487-4 · ExternalCitation · doi-reference
Functional and anatomical outcomes of faricimab in previously treated wet age-related macular degeneration: systematic review and pooled analysis
10.1007/s40123-025-01181-4 · ExternalCitation · doi-reference
Predicting visual outcomes in choroidal osteoma treated with anti-vascular endothelial growth factor
10.1016/j.ajo.2022.08.007 · ExternalCitation · doi-reference
Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials
10.1016/j.ophtha.2023.12.026 · ExternalCitation · doi-reference
TENAYA And LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2
10.1016/j.ophtha.2024.02.014 · ExternalCitation · doi-reference
Anatomic outcomes with faricimab vs aflibercept in the head-to-head dosing phase of the TENAYA/LUCERNE trials in neovascular age-related macular degeneration
10.1016/j.ophtha.2024.11.023 · ExternalCitation · doi-reference
Clinical features and therapeutic management of choroidal osteoma: a systematic review
10.1016/j.survophthal.2023.06.002 · ExternalCitation · doi-reference
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomized, double-masked, phase 3, non-inferiority trials
10.1016/s0140-6736(22)00010-1 · ExternalCitation · doi-reference
Intravitreal bevacizumab monotherapy for choroidal neovascularisation secondary to choroidal osteoma
10.1038/eye.2016.50 · ExternalCitation · doi-reference
Bilaterale chorioidale osteome
10.1055/s-2008-1045680 · ExternalCitation · doi-reference
Outcomes of anti–vascular endothelial growth factor therapy in the management of choroidal neovascularization associated with choroidal osteoma
10.1097/iae.0000000000000187 · ExternalCitation · doi-reference
Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma
10.1097/iae.0b013e3181c720ca · ExternalCitation · doi-reference
Choroidal osteoma: the varied response of subretinal fluid to anti-VEGF agents
10.1136/bcr-2020-234357 · ExternalCitation · doi-reference
Faricimab for choroidal neovascular membrane secondary to choroidal osteoma: a case report
10.1177/03000605261445216 · ExternalCitation · doi-reference
Choroidal neovascular membranes in retinal and choroidal tumors: origins, mechanisms, and effects
10.3390/ijms24021064 · ExternalCitation · doi-reference
Anti-vascular endothelial growth factors for choroidal neovascularization secondary to choroidal osteoma: long-term results
10.4103/0974-620x.169908 · ExternalCitation · doi-reference
Antivascular endothelial growth factorsfor the management of choroidal neovascularization associated with choroidal osteoma: a case study-based review
10.4103/joco.joco_74_24 · ExternalCitation · doi-reference
